Compare KPTI & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | LSBK |
|---|---|---|
| Founded | 2008 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 110.0M |
| IPO Year | 2013 | 2006 |
| Metric | KPTI | LSBK |
|---|---|---|
| Price | $6.78 | $14.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | ★ 174.4K | 17.4K |
| Earning Date | 11-03-2025 | 01-23-2026 |
| Dividend Yield | N/A | ★ 2.39% |
| EPS Growth | N/A | ★ 105.28 |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $142,530,000.00 | $27,774,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $3.18 | N/A |
| P/E Ratio | ★ N/A | $12.47 |
| Revenue Growth | N/A | ★ 9.61 |
| 52 Week Low | $3.51 | $11.50 |
| 52 Week High | $12.45 | $16.95 |
| Indicator | KPTI | LSBK |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 69.61 |
| Support Level | $5.70 | $14.75 |
| Resistance Level | $7.48 | $15.10 |
| Average True Range (ATR) | 0.45 | 0.24 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 69.78 | 96.15 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.